---
title: "Sarepta Therapeutics, Inc. (SRPT.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SRPT.US.md"
symbol: "SRPT.US"
name: "Sarepta Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-04-16T13:53:16.799Z"
locales:
  - [en](https://longbridge.com/en/quote/SRPT.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SRPT.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SRPT.US.md)
---

# Sarepta Therapeutics, Inc. (SRPT.US)

## Company Overview

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.sarepta.com](https://www.sarepta.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-16T04:30:16.000Z

**Overall: C (0.59)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 97 / 393 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 15.58% |  |
| Net Profit YoY | -403.27% |  |
| P/B Ratio | 2.00 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2281427745.56 |  |
| Revenue | 2198237000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -53.47% | E |
| Profit Margin | -32.45% | E |
| Gross Margin | -7.43% | E |
| Revenue YoY | 15.58% | B |
| Net Profit YoY | -403.27% | E |
| Total Assets YoY | -15.48% | E |
| Net Assets YoY | -25.34% | E |
| Cash Flow Margin | 28.80% | C |
| OCF YoY | 15.58% | B |
| Turnover | 0.60 | B |
| Gearing Ratio | 65.95% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Sarepta Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "15.58%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-403.27%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "2281427745.56",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2198237000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-53.47%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-32.45%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-7.43%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "15.58%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-403.27%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-15.48%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-25.34%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "28.80%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "15.58%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.60",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "65.95%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.20 | 304/393 | 26.06 | 25.10 | 22.78 |
| PB | 2.00 | 174/393 | 2.01 | 1.63 | 1.40 |
| PS (TTM) | 1.04 | 23/393 | 1.04 | 0.88 | 0.76 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 03 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 04 | Vertex Pharma (VRTX.US) | A | B | C | B | C | B |
| 05 | Regeneron Pharma (REGN.US) | A | C | C | B | C | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-15T04:00:00.000Z

Total Analysts: **25**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 7 | 28% |
| Hold | 13 | 52% |
| Underweight | 2 | 8% |
| Sell | 3 | 12% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 21.38 |
| Highest Target | 38.00 |
| Lowest Target | 5.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/SRPT.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/SRPT.US/norm.md)
- [Related News](https://longbridge.com/en/quote/SRPT.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/SRPT.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**